Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA3F2X
|
|||
| Drug Name |
TP-6076
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Enterobacteriaceae infection [ICD-11: MG50.C; ICD-10: U82.2] | Phase 1 | [1] | |
| Multidrug resistant infection [ICD-11: MG51; ICD-10: A00-B99] | Phase 1 | [1] | ||
| Company |
Tetraphase Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial 30S ribosomal RNA (Bact 30S rRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03691584) Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers (BAL). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.